The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(E)-N4-(4-(3-([1,4'-bipiperidin]-1'-yl)prop-1-en-1-yl)benzyl)-N2,N2-dimethyl-N4-neopentyl-pyrimidine-2,4-diamine ID: ALA4066364
PubChem CID: 137632825
Max Phase: Preclinical
Molecular Formula: C31H48N6
Molecular Weight: 504.77
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CN(C)c1nccc(N(Cc2ccc(/C=C/CN3CCC(N4CCCCC4)CC3)cc2)CC(C)(C)C)n1
Standard InChI: InChI=1S/C31H48N6/c1-31(2,3)25-37(29-15-18-32-30(33-29)34(4)5)24-27-13-11-26(12-14-27)10-9-19-35-22-16-28(17-23-35)36-20-7-6-8-21-36/h9-15,18,28H,6-8,16-17,19-25H2,1-5H3/b10-9+
Standard InChI Key: RKRJQFHTDJAFLJ-MDZDMXLPSA-N
Molfile:
RDKit 2D
37 40 0 0 0 0 0 0 0 0999 V2000
16.7385 -27.9526 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.7373 -28.7825 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.4550 -29.1946 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.1743 -28.7821 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.1715 -27.9489 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.4532 -27.5364 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.4508 -26.7088 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.1668 -26.2949 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.7322 -26.2991 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.7298 -25.4715 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.0112 -25.0577 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.4458 -25.0534 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.7233 -24.6420 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.8812 -26.7044 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.8815 -27.5294 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.5992 -27.9431 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.3162 -27.5250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.3111 -26.6931 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.5928 -26.2873 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.0332 -27.9342 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.7442 -27.5188 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.4595 -27.9271 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.1705 -27.5117 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
23.8851 -27.9229 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.5941 -27.5111 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.5942 -26.6873 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.8791 -26.2769 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.1640 -26.6904 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.3027 -26.2768 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.0162 -26.6898 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.7267 -26.2807 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.7300 -25.4569 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.0165 -25.0438 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.2997 -25.4546 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.8889 -29.1944 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
19.6032 -28.7817 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.8891 -30.0194 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
6 7 1 0
7 8 1 0
7 9 1 0
9 10 1 0
10 11 1 0
10 12 1 0
10 13 1 0
8 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 14 1 0
17 20 1 0
20 21 2 0
21 22 1 0
22 23 1 0
23 24 1 0
23 28 1 0
24 25 1 0
25 26 1 0
26 27 1 0
27 28 1 0
29 30 1 0
29 34 1 0
30 31 1 0
31 32 1 0
32 33 1 0
33 34 1 0
26 29 1 0
4 35 1 0
35 36 1 0
35 37 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 504.77Molecular Weight (Monoisotopic): 504.3940AlogP: 5.56#Rotatable Bonds: 9Polar Surface Area: 38.74Molecular Species: BASEHBA: 6HBD: ┄#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): ┄#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 10.05CX LogP: 6.31CX LogD: 3.56Aromatic Rings: 2Heavy Atoms: 37QED Weighted: 0.45Np Likeness Score: -1.03
References 1. Miltz W, Velcicky J, Dawson J, Littlewood-Evans A, Ludwig MG, Seuwen K, Feifel R, Oberhauser B, Meyer A, Gabriel D, Nash M, Loetscher P.. (2017) Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis., 25 (16): [PMID:28689977 ] [10.1016/j.bmc.2017.06.050 ]